Sodium Cromoglicate [4%] interactions

Conditions

Conditions in which Sodium Cromoglicate [4%] needs care, as documented in this source.

• Liver Diseases

  Minor

  Systemically absorbed cromolyn is eliminated almost equally by renal and biliary routes. Although less than 1% of an orally ingested dose and approximately 8% of an orally inhaled dose is systemically available, the manufacturers recommend that a dosage reduction be considered in patients with impaired renal or hepatic function.

  7 sources

  1. Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST "Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique." J Pharmacol Exp Ther 241 (1987): 1028-32
  2. Rosenberg JL, Edlow D, Sneider R "Liver disease and vasculitis in a patient taking cromolyn." Arch Intern Med 138 (1978): 989-91
  3. Neale MG, Brown K, Hodder RW, Auty RM "The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration." Br J Clin Pharmacol 22 (1986): 373-82
  4. Fuller RW, Collier JG "The pharmacokinetic assessment of sodium cromoglycate." J Pharm Pharmacol 35 (1983): 289-92
  5. Walker SR, Evans ME, Richards AJ, Paterson JW "The fate of [14C]disodium cromoglycate in man." J Pharm Pharmacol 24 (1972): 525-31
  6. "Product Information. Intal (cromolyn)." Rhone Poulenc Rorer (2001):
  7. "Product Information. Gastrocrom (cromolyn)." Rhone Poulenc Rorer (2001):